Abstract The molecular mechanisms controlling DNA-damage-induced apoptosis of human embryonic stem cells (hESC) are poorly understood. Here we investigate the role of p53 in etoposide-induced apoptosis. We show that p53 is constitutively expressed at high levels in the cytoplasm of hESC. Etoposide treatment results in a rapid and extensive induction of apoptosis and leads to a further increase in p53 and PUMA expression as well as Bax processing. p53 both translocates to the nucleus and associates with the mitochondria, accompanied by colocalization of Bax with Mcl1. hESC stably transduced with p53 shRNA display 80% reduction of endogenous p53 and exhibit an 80% reduction in etoposide-induced apoptosis accompanied by constitutive downregulation of Bax and an attenuated upregulation of PUMA. Our data further show that undifferentiated hESC that express Oct4 are much more sensitive to etoposide-induced apoptosis than their more differentiated progeny. Our study demonstrates that p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular mechanism of DNA-damage-induced apoptosis in hESC.
Introduction
Human embryonic stem cell (hESC) lines are established from the inner cell mass of the blastocyst and differentiate into all cell lineages of the body. Although hESC grown under standard culture conditions on full-density feeder layers display unlimited self-renewal in vitro, they display remarkable genetic stability and do not show morphological changes characteristic of transformation. This could be due to both efficient DNA repair and the selective induction of apoptosis in hESC that have sustained DNA damage. DNA damage response and cell-cycle regulation differ markedly between mouse embryonic stem cells (mESC) and somatic cells (Hong and Stambrook, 2004) . The spontaneous mutation frequency in mouse somatic cells is approximately 100-fold higher than in mESC. mESC also lack a G1 checkpoint and are hypersensitive to ionizing radiation and other DNA-damaging agents (Hong and Stambrook, 2004) . These characteristics facilitate apoptosis and the removal of cells with a mutational burden from the population.
The tumor suppressor p53 plays a central role in suppressing tumorigenesis by inducing cell cycle arrest or apoptosis (Godefroy et al., 2004) . Indeed, mutations of the p53 gene occur in approximately 50% of human cancers (Hollstein et al., 1991; Hussain and Harris, 1998; Levine, 1997) . The role of p53 in guarding both mouse and human ES cells from the consequences of DNA-damage apoptosis remains largely unclear. While some investigators argue that p53 is nonfunctional in undifferentiated mESC (Aladjem et al., 1998) , others show that p53 is involved in both UV-induced apoptosis (Chao et al., 2000; Xu et al., 2002) and differentiation (Sabapathy et al., 1997) . Recently p53 was shown to be involved in UV-induced apoptosis of hESC (Qin et al., 2007) without modulation of p53 target gene expression.
The topoisomerase II inhibitor etoposide is an antineoplastic drug that has been widely used to couple DNA damage to apoptosis (Karpinich et al., 2002) . Topoisomerase II is a nuclear enzyme that functions during both DNA replication and transcription (Hande, 1998) . Topoisomerase II prevents "knots" from forming in DNA by allowing the passage of an intact segment of the helical DNA through a transient doublestrand break (Burden and Osheroff, 1998) . Etoposide stabilizes the complex formed by topoisomerase II and the 5′-cleaved ends of the DNA, thus forming stable (nonrepairable) protein-linked DNA double-strand breaks (Burden and Osheroff, 1998) . Cells are able to recognize such DNA damage and, in turn, to eliminate the injured cells by p53-mediated apoptosis.
Induction of apoptosis by p53 can occur via both transcription-independent and transcription dependent pathways. The classical transcription-dependent pathway involves stabilization of p53 protein via a range of posttranslational modifications, nuclear translocation, and subsequent transactivation of proapoptotic genes, such as PUMA, Noxa, Bax, p53, AIP1, Apaf-1, and PERP, as well as repression of antiapoptotic genes such as Bcl2 and IAPs (Levine, 1997; Lu, 2005) . p53 can also trigger apoptosis via a transcriptionindependent pathway that involves rapid translocation of a proportion of total cellular p53 directly to the mitochondria and interaction with the Bcl2 family of regulators of mitochondrial permeability (Chipuk et al., 2004; Erster et al., 2004; Leu et al., 2004; Mihara et al., 2003) . Here we show that p53 is required for etoposide-induced apoptosis of hESC and that the p53 response in these cells involves both mitochondrial and nuclear apoptotic pathways.
Results hESC are very sensitive to etoposide and exhibit classic apoptotic features
In response to inhibition of topoisomerase II with etoposide, hESC show an increase in apoptosis in a concentration-and time-dependent manner (Figs. 1A and 1B) . Indeed, hESC appear to be far more sensitive to etoposide-induced apoptosis than other cell lines or primary cell cultures (Karpinich et al., 2002 (Karpinich et al., , 2006 Liu and Joel, 2003) . As shown in Fig. S2C the human cell lines HT1080, 293FT, and CFPac-1 treated with 0.17 μM etoposide for 24 h display 3, 12, and 10% TUNELpositive apoptotic cells, while hESC (HES-2) display more than 70% apoptosis after identical treatment, as also shown in Fig.   1B . Etoposide-induced apoptosis of hESC proceeds rapidly, with more than 70% of hESC undergoing apoptosis after 24 h incubation in the presence of 170 nM etoposide.
To confirm that hESC display hallmarks of apoptosis in response to DNA damage (see for review Lawen, 2003) , we incubated hESC cultures with etoposide for various lengths of time and assessed mitochondrial cytochrome c release into the cytosol, caspase-3 activation, DNA laddering, and nuclear condensation. Incubation with etoposide (340 nM) for 3 h causes an increase in soluble cytochrome c in the cytosol of hESC, without affecting the total amount of intracellular cytochrome c (Fig. 1C) . Furthermore, using an antibody specific to activated caspase-3 we show that hESC treated with etoposide for 3 h display caspase-3 activation and that this activation is inhibited by the general caspase inhibitor zVADfmk (Fig. 1D) . By 3 to 4 h after addition of etoposide, hESC start to display the classical 210-bp DNA laddering pattern of apoptosis accompanied by the nuclear condensation (Fig. 1E ) and fragmentation typical of apoptosis (Fig. 1F) . There is no increase in necrotic cells over the time period during which we observed the four diagnostic features of apoptosis (Fig. 1G ).
Etoposide-induced apoptosis of hESC requires caspase activation and is partially sensitive to cycloheximide
Cultures of hESC display a high rate of "spontaneous" apoptosis, with 15% of hESC undergoing apoptosis daily under optimal culture conditions. Caspases are centrally involved in the regulation and execution of the apoptotic program (Thornberry and Lazebnik, 1998) and caspase-3 is activated in etoposide-treated hESC cultures (Fig. 1D ). To determine whether caspases play a functional role in etoposide-induced and spontaneous apoptosis of hESC, we incubated hESC with the general caspase inhibitor zVAD-fmk prior to etoposide treatment. As shown in Fig. 1H , zVAD-fmk totally inhibits etoposide-induced, but not spontaneous, apoptosis of hESC. Similarly, cycloheximide, an inhibitor of protein translation, is able to prevent 50% of etoposide-induced apoptosis but has no effect on spontaneous apoptosis. These data therefore indicate that hESC treated with etoposide undergo caspaseand protein translation-dependent apoptosis, whereas spontaneous apoptosis proceeds via caspase-and translationindependent pathways.
We did not observe any effect of bongkrekic acid (data not shown), an inhibitor of the adenine nucleotide translocator and mitochondrial permeability transition pore formation (Pastorino and Hoek, 2000; Scarlett et al., 2000) , on spontaneous or etoposide-induced apoptosis of hESC. In agreement with this observation, we could not detect any loss of mitochondrial membrane potential, measured by JC-1 uptake, during the first 4 h of induction of apoptosis with etoposide (data not shown), despite the fact that cytochrome c release in the cytosol was already detected at 3 h. Cyclosporin A, an inhibitor of both mitochondrial permeability transition and calcineurin, induced apoptosis by itself and did not inhibit etoposide-induced apoptosis (results not shown). Preincubation with leptomycin B, a nuclear export inhibitor, or cyclic pifithrin-α, a purported inhibitor of p53-mediated transcription (Komarov et al., 1999) , also had no or only a very minor inhibitory effect on etoposide-induced hESC apoptosis. This is perhaps not surprising since the efficacy of pifithrin-α as an inhibitor of p53 transactivation activity is highly questionable (Walton et al., 2005) . Pifithrin-μ, a compound that inhibits association of p53 with mitochondria (Strom et al., 2006) , was found to reduce etoposide induced apoptosis of hESC by 50% (Fig. 1H ).
The state of differentiation of hESC affects their sensitivity to etoposide-induced apoptosis hESC cultured on mouse embryonic fibroblast feeder cells in the presence of knockout serum replacement + 4 ng/ml b-FGF (Amit et al., 2004) appear to be a morphologically homogeneous population of undifferentiated cells. However, hESC cultured under these conditions are heterogeneous and display various degrees of differentiation as judged by the expression of the stem cell marker Oct4 when assayed by immunofluorescence and flow cytometry (Figs. S1 and S2 ). Cells at the outer rim of the hESC colonies display reduced expression of Oct4 and are more resistant to etoposideinduced apoptosis than undifferentiated hESC in the center of the colonies (Fig. S1A) .
To quantify this phenomenon, we double-labeled etoposide-treated HES-2 and HES-4 cells with both TUNEL and antibody directed against the stem cell marker Oct4. As shown in Fig. 2 , the survival of the Oct4-expressing hESC (∼70% of the culture) was reduced to less than 10% within 18 h after etoposide treatment, which was accompanied by an increase in apoptosis from 10 to 70%. Within this time frame the proportion of surviving Oct4-negative cells was not significantly reduced, indicating that differentiated hESC are much more resistant to etoposide-induced apoptosis than their less differentiated counterparts. To highlight this effect of differentiation status on apoptosis we show the results for the HES-4 cell line, which displays a higher degree of spontaneous differentiation than other hESC lines. Similar results were obtained for the HES-2 cell line (data not shown).
Expression analysis of several pro-and antiapoptotic proteins in hESC
To determine whether hESC express established regulators of p53-dependent apoptosis, we used immunostaining of in situ-fixed hESC cultures to detect proteins that are known to possess apoptotic or antiapoptotic activities. Fig. 3 shows that p53, Hdm2, Hdm4, Mcl1, Bax, and p14ARF are expressed in the HES-4 cell line, whereas Bcl2 was undetectable. Similar results were obtained for the HES-2 and HES-3 cell lines. In the majority of undifferentiated hESC, p53 has a cytoplasmic localization with only very few cells at the edge of the colonies displaying nuclear p53 staining detected by the DO-1 antibody. Similar results were obtained using a different anti-p53 antibody (pAB1801; Figs. 3B and 3C). The high levels of cytoplasmic expression of p53 in untreated hESC were confirmed by Western blotting of cytosolic protein extracts from hESC ( Fig. 1C) . HES-2 cells were treated with 340 nM etoposide for 1, 2, or 3 h and permeabilized with digitonin. Proteins in the soluble (S-supernatant) and insoluble (P-pellet) fractions were resolved on separate 15% polyacrylamide gels and Western blotting was performed with p53, cytochrome c, lamin B (nuclear membrane protein), and GAPDH (cytosolic protein) antibodies. (D) Caspase-3 activation. HES-2 cells were preincubated with 25 μM zVAD-fmk or vehicle for 30 min and then treated with 340 nM etoposide for 3 h. PFA-fixed adherent colonies were immunostained for cleaved caspase-3 and nuclei visualized with DAPI. Scale bars, 200 μm. (E) DNA laddering. HES-2 cells were treated with 340 nM etoposide for 2 to 18 h and apoptotic bodies and cells were harvested at the indicated time points. DNA was collected and separated on a 1.5% agarose gel. A 1 kb DNA ladder (Invitrogen) was used as a size standard. (F) Chromatin condensation. HES-2 cells were treated with 340 nM etoposide for 6 h, fixed with 4% PFA, and stained with DAPI. The arrow indicates a human embryonic stem cell with the typical condensed fragmented appearance of an apoptotic cell. Scale bar, 50 μm. (G) Etoposide does not induce necrosis. HES-2 cells were treated with 340 nM etoposide for up to 6 h and apoptotic bodies and cells harvested at the indicated time points. Cells were then incubated with green fluorescence reactive dye (LIVE/DEAD Fixable Dead Cell stain) diluted in KSR medium for 30 min on ice in the dark, fixed in 3.7% PFA, and analyzed by flow cytometry. A representative experiment of three independent experiments is shown. (H) HES-2 cells were preincubated with vehicle alone or with inhibitor (25 μM zVAD-fmk for 30 min, 1 μg/ml cycloheximide for 30 min, 10 μM cyclic pifithrin-α (cPFT) for 1 h, or 10 μM pifithrin-μ for 1 h) and subsequently exposed to 170 nM etoposide for 18 h. Floating and adherent cells were harvested, stained with TUNEL, and analyzed by flow cytometry. Results are expressed as percentage means ± SD (n = 3). Similar results were obtained with HES-4 cells in each assay.
Etoposide-induced apoptosis in hESC dramatically alters subcellular localization of p53, Bax, and Mcl1
In untreated undifferentiated hESC, p53 resides mainly in the cytosol in two forms, a soluble fraction and a particulate fraction, as judged by immunofluorescence detection (Fig. 3A ) and cell fractionation (Fig. 1C) . Four hours after etoposide treatment we detect colocalization of p53 with the mitochondrial marker antibody 1E6 (Banbury, 1994) , suggesting that p53 associates with this organelle. During incubation with etoposide, the subcellular localization of the mitochondria themselves changes from a small punctate distribution throughout the cytosol to large aggregates of mitochondria in a perinuclear region that stain strongly for p53. Simultaneously, an increasing proportion of hESC display nuclear staining for p53 (Figs. 4A and 4B) . These observations suggest that p53 translocates both to the mitochondria and to the nucleus in response to etoposide treatment. One of the prerequisites of mitochondrial permeability transition and cytochrome c release is thought to be the insertion of Bax into the outer mitochondrial membrane. When we examined the subcellular localization of Bax and Mcl1 between 3 and 18 h after etoposide treatment, Bax increasingly colocalized with Mcl1 in perinuclear structures reminiscent of the mitochondrial aggregates described above (Fig. 4C ).
Altered expression of key apoptosis regulators upon etoposide-induced apoptosis in hESC
In most model systems, etoposide-induced apoptosis is dependent on p53 (Karpinich et al., 2002; Lowe et al., 1993; Yin et al., 2000) . In agreement with these previous observations, we detect an increase in p53 expression as early as 3 h after etoposide addition. Expression of p53 then peaks around 6-9 h of exposure to etoposide and wanes thereafter (Fig. 5A) . PUMA, one of the downstream targets of p53, is upregulated between 4.5 and 6 h after exposure to etoposide, as is nuclear p53. Furthermore, consistent with the release of cytochrome c at 3 h after exposure to etoposide, increased activation of caspase-3 is maintained for 6 to 8 h after etoposide addition. Similar kinetics of upregulation was observed for Hdm2. By contrast, no alteration in Mcl1, Hdm4, Noxa, or Oct4 expression was found in etoposide-treated hESC (Fig. 5A) . However, Nanog was downregulated in hESC after etoposide-induced upregulation of p53, in agreement with the previously reported (Lin et al., 2005) ability of p53 to suppress Nanog expression in mESC. We detect no, or only very slight, upregulation of the p53 target Bax in response to etoposide treatment but a clear increase in processing of Bax to the more potent proapoptotic 18-kDa form with time (Gao and Dou, 2000; Wood and Newcomb, 2000) . We did not detect expression of p21, a potential downstream target of p53 involved in cell cycle arrest in many cellular model systems, in either untreated or etoposide-treated hESC by Western blotting or immunofluorescence (data not shown). This was not due to an inability of the antibody to detect p21, since we could detect robust expression of p21 in protein extracts of human embryonic fibroblasts (data not shown). Since cycloheximide is able to inhibit 50% of etoposide-induced apoptosis, we were interested in determining how this relates to the expression of p53-regulated apoptosis modulators. As shown in Fig. 5B preincubation with cycloheximide does not prevent the upregulation of p53, suggesting that the majority of its increased expression is due to increased stabilization of p53 protein and not to de novo synthesis. However, the expression of Bax, PUMA, and Mcl1 is clearly reduced by this protein synthesis inhibitor, suggesting that Bax and PUMA may be important determinants of etoposide-induced apoptosis of hESC.
p53 is required for etoposide-induced apoptosis
To investigate the role of p53 in etoposide-induced apoptosis of hESC we stably transduced HES-2 hESC with a lentivirus carrying short hairpin RNA (shRNA) designed to knock down p53 mRNA. As shown in Figs. 6B and 6C, p53 shRNAtransduced hESC (i) constitutively express only 20% of p53 protein compared to untransduced or control GFP shRNAtransduced hESC and (ii) display a reduced upregulation of p53 in response to etoposide addition. These data are consistent with the 80% reduction in etoposide-induced apoptosis observed in p53 shRNA-transduced hESC (Fig.  6A ). These data demonstrate that etoposide-induced apoptosis of hESC is dependent on p53. The reduction of p53-dependent apoptosis in the p53 shRNA-transduced hESC is accompanied by a constitutive downregulation of Bax expression and an attenuated upregulation of PUMA in response to etoposide addition. These data therefore strongly suggest that the reduction of etoposide-induced apoptosis in p53-knockdown hESC is due to a reduced upregulation of PUMA and a constitutively reduced expression of Bax. The reduced sensitivity of the p53 shRNAtransduced hESC to etoposide-induced apoptosis is not due to an increased differentiation.
p53 is required for spontaneous apoptosis
Between 10 and 15% of hESC (HES-2, HES-3, and HES-4) grown under standard serum-free culture conditions (Amit et al., 2004) undergo spontaneous apoptosis over an 18-h period. As shown in Fig. 6 , HES-2 stably transduced with p53 shRNA and displaying only 20% residual p53 expression compared to untransduced or GFP shRNA-transduced hESC display a reduction in spontaneous apoptosis from 11.4 ± 5.4 to only 2.4 ± 1.0% (Fig. 6A) . GFP shRNA-transduced HES-2 cells or nontransduced hESC continued to display 15% spontaneous apoptosis, indicating that the reduction in spontaneous apoptosis is not due to the lentiviral transduction per se. Although the reason for the relatively high rate of spontaneous apoptosis in hESC serum-free culture is unknown, our data indicate that spontaneous apoptosis is dependent on p53.
Transcriptome analysis of GFP and p53 shRNA-transduced hESC Three replicates of hESC (HES-2 and HES-4) transduced with either GFP or p53 shRNA were FACS sorted using the cell surface markers CD9 and GCTM2 to obtain a population of undifferentiated hESC. RNA was isolated from these fractions and subjected to microarray analysis on the 46K Human Illumina platform. The data shown in Fig. S3 demonstrate that biological replicates of transduced lines display highly similar transcriptome profiles and that a similar set of genes was consistently altered between p53 and GFP shRNAtransduced lines, independent of the HES lines used. Indeed, 70% of differentially expressed genes were found to contain p53 binding sites in their promoters. A selection of five consistently differentially expressed genes between GFP and p53 shRNA-transduced hESC is shown in the table in Fig. S3 . These p53-regulated genes were previously shown to exhibit binding of p53 to consensus p53 binding sites in their promoters by CHIP analysis (Wei et al., 2006) . Discussion hESC are highly susceptible to spontaneous and etoposide-induced apoptosis p53 is considered a critical regulator of genomic integrity because of its ability to trigger apoptosis and/or cell cycle arrest in response to genotoxic stress. Because embryonic stem cells display remarkable genomic stability and are highly sensitive to ionizing radiation and other DNA-damaging agents we examined in detail the role of p53 in the regulation of apoptosis of human embryonic stem cells. To this end we opted to use etoposide treatment since this drug has been shown to activate the p53 pathway specifically in many model systems. Our data demonstrate that etoposide apoptosis of hESC requires p53. We further show that hESC display the characteristic features of apoptosis and, like mESC, are extremely sensitive to both spontaneous and etoposide-induced apoptosis. Spontaneous apoptosis of cultured hESC is mediated by p53, since reduction of p53 expression in HES-2 causes a commensurate reduction in apoptosis. These data are in agreement with a recent study by Qin et al. (2007) , who also showed that spontaneous and UV-induced apoptosis of hESC is controlled by p53. If p53-mediated spontaneous apoptosis is involved in eliminating genetically damaged cells from the stem cell population, reduction of p53 function should result in an increased frequency of chromosomal abnormalities and genetic mutations. We are currently testing this hypothesis. The karyotypes of the GFP shRNA-transduced control HES-2 and p53 shRNA-transduced HES-2 cells were found to be normal at weekly passage 13 (results not shown). shRNA-transduced and GFP shRNA-transduced (control) hESC were harvested 4.5, 9, and 18 h after treatment with 170 nM etoposide. Cells were subsequently PFA-fixed, labeled with TUNEL, immunostained with the stem cell marker Oct4, and analyzed by flow cytometry. Results shown are expressed as percentage means ± SD (n = 4). (B) Downregulation of p53 and p53 downstream targets Bax and PUMA in p53 shRNA-transduced HES-2 cells. HES-2 cells stably expressing p53 shRNA or GFP shRNA were harvested 4.5 and 9 h after treatment with 170 nM etoposide. Protein extracts were boiled in Laemmli buffer, resolved on separate polyacrylamide gels, and analyzed by Western blotting with p53, PUMA, Bax, Nanog, and Oct4 antibodies. β-Tubulin was used to ensure equal protein loading. (C) Quantification of protein expression using software-based densitometric analysis on cross-reactive bands and the β-tubulin loading controls. A representative example of three independent experiments is shown. 
Differentiation of hESC reduces their sensitivity to etoposide-induced apoptosis
The sensitivity of hESC (HES-2 and HES-4) to etoposide-induced apoptosis is dependent on their differentiation status. We show that undifferentiated hESC that express Oct4 are the least resistant to etoposide-induced apoptosis compared to their more differentiated progeny. Clearly the reduction in Oct4 immunoreactivity in apoptotic hESC observed in flowcytometric analysis 6-9 h after etoposide treatment is not due to an increase in differentiation, which proceeds much more slowly over a period of days. Indeed, when analyzed by Western blotting, Oct4 protein expression was not reduced (Fig. S2B) . Given the profound effect of the differentiation status of hESC on their rate of apoptosis we strongly argue that meaningful data on apoptosis in hESC can be obtained only when TUNEL-labeled cells are double labeled with at least one pluripotency marker, as performed in this study. In agreement with our data, undifferentiated mESC were recently shown to be more sensitive to O(6)-methylguanine-induced apoptosis than their differentiated counterparts (Roos et al., 2007) .
Our data further show that p53 has a small but reproducible effect on spontaneous differentiation of cultured hESC as determined by the slight increase in Oct4 expression by FACS in p53 shRNA-transduced hESC lines (91.7 ± 3.4% (n = 5)) compared to the GFP shRNA-transduced controls (83.4 ± 3.2% (n = 5), p b 0.01), similar to what was observed by Qin et al. (2007) .
The mechanism of p53-dependent apoptosis in hESC
Initiation of etoposide-induced apoptosis in hESC commences around 3 h after etoposide addition with translocation of the highly expressed cytosolic p53 protein to the mitochondria and release of cytochrome c. There is no detectable loss of mitochondrial membrane potential, as judged by the maintenance of JC-1 red/green fluorescence. Cytochrome c release from mitochondria without loss of mitochondrial membrane potential has previously been reported (Finucane et al., 1999; Grubb et al., 2001; Krohn et al., 1999) . Because caspase-3 is activated at 3 h after etoposide treatment, we conclude that apoptosome formation and initiation of the apoptotic cascade has already commenced at this stage. The dramatic increase in nuclear p53, which occurs at the same time, suggests that there are two fractions of cytosolic p53 with different functions in apoptosis induction in response to etoposide: one that associates with the mitochondria and one that translocates to the nucleus. In support of this idea, inhibition of p53 association with mitochondria with pifithrin-μ prevents only 50% of etoposide-induced apoptosis of hESC (Fig. 1H) . Nuclear accumulation of p53 is accompanied by an early upregulation of the p53 target gene PUMA, but does not cause an increase in p21. This finding may explain why cells that have initiated apoptosis fail to arrest the cell cycle in G0/G1 (as indicated by flow-cytometric analysis of DAPI-stained hESC cultures (data not shown)). In this respect hESC resemble mouse ES cells (Xu et al., 2002) , which also do not exhibit cell cycle arrest or slowdown upon UV-induced DNA damage. The fact that we observe modulation of only a subset of p53 target genes (PUMA, Hdm2, Nanog) in response to p53 upregulation suggests that p53 exhibits target specificity, which may be due, for example, to differences in p53 posttranslational modifications, histone modifications, or interactions with other transcription factors.
Our data are in contrast to the study by Qin et al. (2007) , which indicated that UV-and γ-radiation-induced apoptosis of hESC, although p53 dependent, does not lead to accumulation of Bax or Hdm2 and does not cause activation of any p53 downstream target genes in luciferase reporter assays. The authors postulated that posttranslational modifications of p53 render the p53 protein transcriptionally inactive without interfering with p53's ability to repress Oct4 and Nanog expression. It was consequently concluded that p53 induces apoptosis solely through a mitochondrial pathway. We find, however, that, similar to what we observe for etoposide-induced apoptosis, γ-radiation (1 Gy)-induced apoptosis of hESC causes increased p53 expression that is accompanied by upregulation of the p53 downstream target genes PUMA and Hdm2 (Fig. S3B ). These differences may be due to intrinsic cell line differences (H1 hESC vs HES-2, HES-3, and HES-4 in our study), the passage number of the hESC (p42-68 H1 vs less than p15 in our study), or the method of propagation (dispase vs collagenase in our study). Indeed, there is an increasing amount of evidence to suggest that hESC can adapt to culture conditions with increasing time in culture (Baker et al., 2007) and that these changes can impact on the regulation of apoptosis (Herszfeld et al., 2006) . Alternatively, some of the differing data between the two studies may be due to mechanistic differences between the responses of hESC to the different apoptotic stimuli, namely UV irradiation and etoposide treatment (Attardi et al., 2004) . For example, UVB treatment generally causes activation of p38 and/or wip1 (Takekawa et al., 2000) . p38-mediated phosphorylation and stabilization of p53 can subsequently cause cytoplasmic sequestration of wild-type p53, leading to an absence of p53 target gene modulation (Chouinard et al., 2002) , while wip1 expression has been shown to suppress both p53-mediated transcription and apoptosis in response to UV radiation (Takekawa et al., 2000) . Neither p38 nor WIP1 has previously been implicated in etoposide-induced apoptosis.
Microarray analysis of untreated p53 shRNA-knockdown hESC and GFP shRNA-transduced control hESC shows that there are highly similar sets of up-and downregulated mRNAs in both HES-2 and HES-4 p53 shRNA-transduced hESC in three independent biological replicates (Fig. S3) . Bioinformatic analysis shows that more than 70% of these genes contain p53 binding sites in their promoters. We have highlighted five p53-regulated genes that were previously shown to bind p53 in their promoters (Wei et al., 2006) . These data strongly suggest that the observed gene expression changes are not due to viral insertion effects and that even without etoposide treatment p53 is involved in the regulation of several known p53-controlled genes.
hESC express high levels of p53 protein in the cytosol under standard culture conditions. In mESC, cytoplasmic p53 protein translocates inefficiently to the nucleus upon nucleotide depletion and the cells undergo p53-independent apoptosis in response to DNA damage. This response is clearly different in hESC, which show an increase in nuclear p53 expression after etoposide treatment. This may be due to differences between the DNA-damage response mechanisms in etoposide-treated cells and in cells exposed to nucleotide depletion or to intrinsic differences between mouse and human ES cells. Reduction of the pool of p53 by lentivirally delivered shRNA leads to a reduced expression of Bax and an attenuated upregulation of PUMA after etoposide treatment, suggesting that these proteins may be critical p53 downstream targets for induction of etoposide-induced apoptosis in hESC. In other model systems PUMA, a BH3-only derepressor molecule, counteracts the antiapoptotic function of Mcl1 and induces a proapoptotic conformational change in Bax . BH3-only Bcl2 family members such as PUMA trigger mitochondrial cytochrome c release without loss of mitochondrial membrane potential (Shimizu and Tsujimoto, 2000) , as is the case in etoposide-treated hESC. Alternatively PUMA may be involved in the release of mitochondrially associated p53 to enhance nuclear p53-mediated apoptotic events further, as recently demonstrated by Chipuk et al. (2005) .
hESC represent a unique cellular model to study p53 regulation of apoptosis, given that they are nontransformed immortal cells with a normal karyotype and cannot be directly compared to long-established cell lines, in which apoptosis pathways are intrinsically altered as part of the transformation process, or even to primary cell cultures, which display senescence, DNA-damage-induced cell cycle arrest, and contact inhibition. The regulation and kinetics of apoptosis in hESC are very similar to those observed for in vivo-irradiated thymocytes, with a rapid p53 transcriptionindependent first wave of apoptosis followed by a second p53 transcription-dependent wave (Erster et al., 2004 ) and a very early upregulation of PUMA and Bax coincident with caspase-3 activation. Our data suggest that in hESC these two waves occur either simultaneously or very soon one after the other. In both model systems, however, the p53-dependent upregulation of PUMA and Bax appears to be a critical determinant. We propose a working model for etoposide-induced apoptosis in hESC (Fig. 7) in which DNA damage leads to stabilization and increased expression of p53 followed by translocation of p53 to both the mitochondria, where it possibly interacts with Mcl1, and the nucleus, where it leads to transcriptional upregulation of PUMA and maintenance of Bax expression. The 18-kDa processed forms of Bax and PUMA next cooperate in triggering cytochrome c release from the mitochondria without loss of membrane potential and this subsequently leads to activation of a caspase-3-dependent apoptotic program. The presence of two simultaneous pathways to induce p53-mediated apoptosis may be a failsafe mechanism of hESC to ensure that abnormal hESC do not contribute to the developing tissues and the germ line.
Material and methods
Cell culture hES cell lines HES-2, HES-3, and HES-4 (Reubinoff et al., 2000) were cultured (a) on a mouse fibroblast feeder (MEF) layer at a density of 6 × 10 4 cells/cm 2 in DMEM with 20% FCS, 1% ITS, 1% pen/strep, 1% l-glutamine, 1% NEAA, and 0.1 mM β-mercaptoethanol using mechanical transfer or (b) with a mouse fibroblast feeder density of 2 × 10 4 cells/cm 2 in KSR medium with 20% KO-serum replacement, 1% l-glutamine, 1% NEAA, 4 ng/ml b-FGF, and 0.1 mM β-mercaptoethanol using 4 mg/ml collagenase (Worthington Biochemical) for serial passaging (Amit et al., 2000) . Cells were plated on Matrigel (BD Biosciences) with MEF-conditioned serum replacement medium as described (Xu et al., 2001) . hES cell lines were used only up to passage 15 when cultured as per Amit et al. (2000) or Xu et al. (2001) .
DNA laddering
hESC and apoptotic bodies were collected and washed with PBS. DNA laddering was determined using standard protocol 2 as described at http://www.sgul.ac.uk/depts/immunology/ dash/group/laddering.html. (Banbury, 1994) . Cells were subsequently counterstained with DAPI (1 μg/ml), mounted with Vectashield mounting medium (Vector), and analyzed using a fluorescence microscope (FluorMicro BX51; Olympus).
Western blotting analysis
hESC were harvested with Cell Dissociation Solution (Sigma) and boiled in Laemmli buffer. Proteins were separated by electrophoresis through 12% SDS-PAGE gels and electrotransferred to Hybond P (Amersham). The membranes were blocked with 4% skim milk powder and incubated with primary antibody overnight at 4°C and reactivity was visualized using appropriate HRP-conjugated secondary antibodies and ECL (Amersham). The primary antibodies, respective dilutions, and sources were p53, 1:1000 (DO-1; Santa Cruz Biotechnology); Mcl1, 1:1000 (Abcam); Hdm2, 1:1000 (SMP14; Sigma); Hdm4, 1:1000 (Abcam); Bax, 1:1000 (DAKO); cleaved caspase-3 (Asp175), 1:1000 (Cell Signaling); β-tubulin, 1:50,000 (Sigma); lamin B, 1:1000 (Calbiochem); GAPDH, 1:4000 (Ambion); cytochrome c, 1:200 (BD Pharmingen); PUMA, 1:1000 (Calbiochem); Bcl2, 1:1000 (Santa Cruz Biotechnology); p21, 1:1000 (BD Pharmingen). Images were acquired using the Bio-Rad Gel ChemiDoc XRS System. Last, software-based densitometric analysis (Gel-Pro Analyser version 3.1; MediaCybernetics) was performed on cross-reactive bands and the β-tubulin loading controls.
Apoptosis and flow cytometry analysis
Etoposide (Sigma) was used as an apoptosis-inducing agent. After the various treatments, adherent cells and floating cells were harvested with Cell Dissociation Solution (Sigma), pooled, and pelleted by centrifugation. Suspensions were subsequently fixed with PFA (2%) and permeabilized with 0.1% Triton X-100 for TUNEL (Roche) labeling as described by the manufacturer and additional labeling with Oct4 1:40 (Santa Cruz Biotechnology) prior to analysis by flow cytometry (Cytometrics FC 500 System; Beckman Coulter). Cyclic pifithrin-α (c-PFT, 10 μM; Sigma), pifithrin-μ (10 μM; Calbiochem), and bongkrekic acid (50 μM; Sigma) were added 1 h before the treatment with etoposide. zVAD-fmk (25 μM; Sigma) and cycloheximide (1 μg/ml; Sigma) were added 30 min before the treatment with etoposide.
Measurement of mitochondrial membrane potential
The MitoProbe JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide) assay kit for flow cytometry (Invitrogen) was used to measure mitochondrial membrane potential according to the manufacturer's instructions. Cells were analyzed by flow cytometry (Cytometrics FC 500 System; Beckman Coulter). In control experiments, cells were incubated with the ionophore carbonyl cyanide 3-chlorophenylhydrazone at 100 μM 5 min prior to the addition of JC-1.
Cell staining for viability
The LIVE/DEAD Fixable Dead Cell stain kit (green fluorescence; Invitrogen) was used to distinguish apoptosis from necrosis. The assay was performed according to the manufacturer's instructions. Cells were analyzed by flow cytometry (Cytometrics FC 500 System; Beckman Coulter).
Lentiviral shRNAi
HES-2 cells were transduced with lentivirus carrying shRNA designed to knock down p53 or GFP using the Block-It Lentiviral RNAi Expression System (Invitrogen), as described by the manufacturer. The p53 shRNA sequences used were the following: p53 top strand, 5′-CGCGCACAGAGGAAGAGAAT-CTCGAAAGATTCTCTTCCTCTGTGTGCGC-3′, and p53 bottom strand, 5′-AAAAGCGCACAGAGGAAGAGAATCTTTTCGAGAT-TCTCTCTTCCTCTGTGCGC-3′; GFP top strand, 5′-CACCGAA-GAAGTCGTGCTGCTTCATCGAAATGAAGCAGCACGACTTCTTC-3′, and GFP bottom strand, 5′-AAAAGAAGAAGTCGTGCTGCTTCAT-TTCGATGAAGCAGCACGACTTCTTC-3′. Cells were plated on Matrigel and infected with lentivirus (m.o.i. of 3). Selection with blasticidin (5 μg/ml) was performed for 1 week after each infection and cells were transferred to flasks with MEF feeders at 2 × 10 4 cells/cm 2 in KSR medium. Apoptosis assays and Western blotting analysis were performed as described above.
